Michael F. Murray, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, has been named the new System Chief of the Division of Genomic Medicine and the Clinical Director of the Institute for Genomic Health at Mount Sinai. He will lead its efforts to harness the power of genomic discovery to develop new ways to prevent and treat diseases, including cancers, heart problems, and genetic disorders. Dr. Murray has distinguished himself as an internationally renowned expert in using DNA-derived information as a screening tool in clinical care, population health, and public health.
NEW YORK, Sept. 26, 2023 /PRNewswire-PRWeb/ — Michael F. Murray, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, has been named the new System Chief of the Division of Genomic Medicine and the Clinical Director of the Institute for Genomic Health at Mount Sinai. He will lead its efforts to harness the power of genomic discovery to develop new ways to prevent and treat diseases, including cancers, heart problems, and genetic disorders.
Dr. Murray has distinguished himself as an internationally renowned expert in using DNA-derived information as a screening tool in clinical care, population health, and public health.
Before joining the Mount Sinai Health System, he led cutting-edge efforts to integrate genomic medicine into clinical care delivery at Harvard Medical School, Geisinger Community Medical Center, and Yale New Haven Health System. These efforts included developing and leading genomic sequencing programs to enable early disease diagnosis and prevention in patients.
Dr. Murray helped develop new ways to translate these data into patient care, enabling large health systems to provide this information to patients and their care providers in order to help improve health outcomes.
In addition to these innovations, Dr. Murray has gained national recognition for his work in genomic medicine education. He was the Founding Director of the Combined Residency in Internal Medicine and Medical Genetics at Brigham and Women’s Hospital in Boston and Director for the “Genetic Basis of Adult Medicine,” an annual continuing medical education course at Harvard Medical School.
Dr. Murray is an alumnus of Pennsylvania State University College of Medicine, and completed further training at Cleveland Clinic, the University of Pennsylvania, and Harvard Medical School. He has co-authored numerous publications in medical, genetic, and infectious disease journals.
Dr. Murray is a member of the board of directors of the American College of Medical Genetics and Genomics.
“With the investment that the Mount Sinai Health System has made in genetics and genomics technology in the clinical and research arenas, we are making an impact upon the care we provide to patients in a significant way,” said Monica Kraft, MD, the Murray M. Rosenberg Professor of Medicine and System Chair of the Department of Medicine at Mount Sinai Health System and Icahn Mount Sinai. “The Department of Medicine’s Division of Genomic Medicine needs a leader who can work with stakeholders across our Health System to seamlessly integrate genetics and genomic science to advance the clinical care that all our adult and pediatric patients receive. Dr. Murray has expertise in this area and comes to us at the right time to make this happen.”
“I am delighted to join hands with the Department of Medicine and welcome Dr. Murray on this exciting bridge-building journey. Together, we will work toward harnessing the power of genomic discovery to pioneer novel strategies for preventing and treating disease, ultimately benefiting patients,” said Eimear Kenny, PhD, a Professor of Medicine, Genetics and Genomic Sciences, and Founding Director of the Institute for Genomic Health at the Icahn School of Medicine at Mount Sinai.
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight- member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.
Ranked 14th nationwide in National Institutes of Health (NIH) funding and among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators, and clinicians work within and across 44 academic departments and 36 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, as well as gastrointestinal and liver diseases.
Icahn Mount Sinai offers highly competitive MD, PhD, and Master’s degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,000 clinical residents and fellows training throughout the Health System. In addition, more than 550 postdoctoral research fellows are in training within the Health System.
A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinai’s technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into healthcare products and services that benefit the public.
Icahn Mount Sinai’s commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the School’s programs.
Through the Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others.
The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai’s location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.
——————————————————-
- Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.
Media Contact
Karin Eskenazi, Mount Sinai, 332-257-1538, [email protected], mountsinai.org
SOURCE Mount Sinai
